Last updated on February 2019

Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor

Brief description of study

This study is being done to look at the role of continuing palbociclib treatment in combination with another type of hormonal therapy (fulvestrant) after disease progression of palbociclib in combination with an aromatase inhibitor.

Detailed Study Description

In this phase II trial, the primary objective is to determine the progression-free survival (PFS) of the cyclin dependent kinase 4/6 inhibitor (CDK4/6i) palbociclib with fulvestrant in women and men with estrogen or progesterone receptor (ER/PR) positive, HER2-negative metastatic breast cancer (MBC) who progressed on treatment with palbociclib and an aromatase inhibitor (AI). The study will also determine the prevalence rate of estrogen receptor (ESR1) and phosphatidylinositol-3-kinase (PI3K) mutations in the study population.

The secondary objectives include evaluating the progression-free survival (PFS) in participants with and without ESR1 mutations, and PI3K mutations through analysis of tumor biopsies and circulating plasma tumor DNA (ptDNA) samples. The study will also describe other alterations in genes and gene products relevant to the cell cycle, drug targets, tumor sensitivity and resistance, and identify novel protein kinases activated in biopsies from participants with hormone refractory MBC who progressed on prior palbociclib and AI. The data will be correlated with tumor subtypes, expression profiles, and candidate phosphoprotein expression with PFS in the study population.

Clinical Study Identifier: NCT02738866

Contact Investigators or Research Sites near you

Start Over

Vered Stearns, M.D.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, MD United States
  Connect »

Raquel Nunes, MD

Kimmel Cancer Center at Johns Hopkins at Sibley Memorial Hospital
Washington, WA United States
  Connect »

Jeanine Werner, MD

Anne Arundel Health System Research Institute, Inc.
Annapolis, MD United States
  Connect »

Antonios Christou, MD

Allegheny Health Network (AHN) - Allegheny General Hospital ONLY
Pittsburgh, PA United States
  Connect »

Terrence Cescon,, MD

Reading Hospital - McGlinn Cancer Institute
West Reading, PA United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.